Scarica l'app Stockscreener
27.62
1.18%
-0.33
Dopo l'orario di chiusura:
27.45
-0.17
-0.62%
Precedente Chiudi:
$27.95
Aprire:
$28.25
Volume 24 ore:
193.54K
Relative Volume:
0.58
Capitalizzazione di mercato:
$1.22B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-3.53%
1M Prestazione:
-10.06%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$27.43
$29.10
Intervallo di 1 settimana:
$27.43
$30.45
Portata 52W:
$24.15
$33.32
Avalyn Pharma Inc Stock (AVLN) Company Profile
Nome
Avalyn Pharma Inc
Settore
Industria
Telefono
(206) 707-0340
Indirizzo
105 W FIRST ST., BOSTON
Compare AVLN vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
27.62 | 1.24B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Avalyn Pharma Inc Borsa (AVLN) Ultime notizie
Avalyn Pharma (NASDAQ:AVLN) Shares Gap DownTime to Sell? - MarketBeat
Avalyn Pharma Inc. Revenue Breakdown – NASDAQ:AVLN - TradingView
AVLN|Avalyn Pharma Ord Shs (Proposed)|Price:27.950|Chg%:-1.780 - TradingKey
Adam H. Golden Net Worth (2026) - GuruFocus
Enterprise value to revenue forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Price to sales forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Price to book forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Avalyn Pharma Inc (AVLN:UW): Stock Price, Quote and News - BNN Bloomberg
Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Rating of "Buy" from Analysts - MarketBeat
Avalyn Pharma (NASDAQ:AVLN) Shares Up 5.3%Here's Why - MarketBeat
Melissa Rhodes Net Worth (2026) - GuruFocus
Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
AVALYN PHARMA INC (AVLN) News Flow - Moomoo
Avalyn Pharma (AVLN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Enterprise value to EBIT forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Enterprise value to EBITDA forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Price to earnings forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Index - marketscreener.com
Avalyn Pharma Inc Actuals & Estimates (NASDAQ:AVLN) - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Value Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Growth Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 3000E Growth Benchmark - marketscreener.com
AVLN Forecast — Price Target — Prediction for 2027 - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell Small Cap Completeness Index - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2500 Index - marketscreener.com
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avalyn Pharma (AVLN) Stock Chart and Price History 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs - BioPharma Dive
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Avalyn Pharma (AVLN) Earnings Date and Reports 2026 - MarketBeat
Avalyn Pharma (AVLN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Why is Avalyn Pharma stock surging today? By Investing.com - Investing.com UK
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone By Investing.com - Investing.com Canada
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial By Investing.com - Investing.com Australia
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis - The Manila Times
Avalyn Pharma Ord Shs (Proposed) (AVLN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead - inkl
Morgan Stanley Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Avalyn Pharma Inc. 2026 Q1 Financial Report and Material Risks Overview - Minichart
Avalyn Pharma 1Q Loss $26.9M >AVLN - Moomoo
Press Release: Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights - Moomoo
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma Inc. 1Q 2026: Net income $(26.9M), EPS $(21.83) — 10-Q Summary - TradingView
Avalyn: Q1 Earnings Snapshot - marketscreener.com
Avalyn Pharma Inc Azioni (AVLN) Dati Finanziari
Non sono disponibili dati finanziari per Avalyn Pharma Inc (AVLN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):